Greenwich LifeSciences (GLSI) Enterprise Value (2020 - 2026)

Greenwich LifeSciences (GLSI) has 7 years of Enterprise Value data on file, last reported at -$6.2 million in Q4 2025.

• Quarterly Enterprise Value fell 50.98% year-over-year to -$6.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$6.2 million (down 50.98% YoY) and the FY2025 annual result came in at -$6.2 million, down 50.98% from the prior year.
• Enterprise Value eased to -$6.2 million in Q4 2025, from -$3.8 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$2.7 million in Q1 2025 to a low of -$30.4 million in Q1 2021.
• A 5-year average of -$13.0 million and a median of -$10.0 million in 2023 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2021 — Enterprise Value slumped 365.15% — and 2025, when it surged 56.75%.
• Tracing GLSI's Enterprise Value over 5 years: stood at -$27.2 million in 2021, then jumped by 50.49% to -$13.5 million in 2022, then soared by 48.1% to -$7.0 million in 2023, then jumped by 41.45% to -$4.1 million in 2024, then tumbled by 50.98% to -$6.2 million in 2025.
• The last three Enterprise Value figures came in at -$6.2 million (Q4 2025), -$3.8 million (Q3 2025), and -$3.1 million (Q2 2025), per Business Quant data.